Background: Odontogenic tumours are a group of rare heterogeneous diseases that range from hamartomatous tissue proliferations to benign and malignant neoplasms. Recurrences can occur after 10 years, so long-term clinical and radiological follow-up is required. The study of the molecular mechanisms involved in the development of these lesions is necessary to identify new prognostic markers. In this study, we evaluate the possible role of nicotinamide N-methyltransferase (NNMT) in ameloblastomas (AM) and odontogenic keratocysts (OKC). Materials and methods: A total of 105 surgical specimens of primary and recurrent lesions were obtained from 55 patients (25 AM, 30 OKC). In particular, 50 AMs (25 primary, 25 recurrences) and 55 OKCs (30 primary, 25 recurrences) were retrieved. We carried out immunohistochemical analyses to evaluate the cytoplasmic expression of NNMT, measuring the percentage of positive cells and the value of NNMT expression intensity. Results: NNMT expression was significantly higher in recurrent than primary AMs (P =.0430). This result was confirmed by staining intensity, showing more cases with moderate/intense staining in recurrent AMs (P =.0470). NNMT expression was significantly lower in recurrent than primary OKC (P =.0014). Staining intensity showed more cases with moderate/intense staining in primary OKCs (P =.0276). Conclusions: This report is the first to evaluate NNMT expression in odontogenic lesions and to demonstrate a differential expression in recurrent AMs and OKCs, suggesting that there is potential for use of NNMT as prognostic marker. © 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
Differential expression of nicotinamide N-methyltransferase in primary and recurrent ameloblastomas and odontogenic keratocysts / Mascitti, M; Sartini, D; Togni, L; Pozzi, V; Rubini, C; Santarelli, A; Emanuelli, M. - In: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0014-2972. - STAMPA. - 50:4(2020). [10.1111/eci.13220]
Differential expression of nicotinamide N-methyltransferase in primary and recurrent ameloblastomas and odontogenic keratocysts
Mascitti MPrimo
Writing – Original Draft Preparation
;Sartini DMethodology
;Togni LMethodology
;Pozzi VMethodology
;Rubini CWriting – Review & Editing
;Santarelli A
Conceptualization
;Emanuelli MConceptualization
2020-01-01
Abstract
Background: Odontogenic tumours are a group of rare heterogeneous diseases that range from hamartomatous tissue proliferations to benign and malignant neoplasms. Recurrences can occur after 10 years, so long-term clinical and radiological follow-up is required. The study of the molecular mechanisms involved in the development of these lesions is necessary to identify new prognostic markers. In this study, we evaluate the possible role of nicotinamide N-methyltransferase (NNMT) in ameloblastomas (AM) and odontogenic keratocysts (OKC). Materials and methods: A total of 105 surgical specimens of primary and recurrent lesions were obtained from 55 patients (25 AM, 30 OKC). In particular, 50 AMs (25 primary, 25 recurrences) and 55 OKCs (30 primary, 25 recurrences) were retrieved. We carried out immunohistochemical analyses to evaluate the cytoplasmic expression of NNMT, measuring the percentage of positive cells and the value of NNMT expression intensity. Results: NNMT expression was significantly higher in recurrent than primary AMs (P =.0430). This result was confirmed by staining intensity, showing more cases with moderate/intense staining in recurrent AMs (P =.0470). NNMT expression was significantly lower in recurrent than primary OKC (P =.0014). Staining intensity showed more cases with moderate/intense staining in primary OKCs (P =.0276). Conclusions: This report is the first to evaluate NNMT expression in odontogenic lesions and to demonstrate a differential expression in recurrent AMs and OKCs, suggesting that there is potential for use of NNMT as prognostic marker. © 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons LtdFile | Dimensione | Formato | |
---|---|---|---|
EJCI 2020.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
1.07 MB
Formato
Adobe PDF
|
1.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Post-print+EJCI+2020.pdf
Open Access dal 02/04/2021
Descrizione: This is the peer reviewed version of the following article: Differential expression of nicotinamide N-methyltransferase in primary and recurrent ameloblastomas and odontogenic keratocysts / Mascitti, M; Sartini, D; Togni, L; Pozzi, V; Rubini, C; Santarelli, A; Emanuelli, M. - In: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0014-2972. - STAMPA. - 50:4(2020), p. 13220. © 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd, which has been published in final form at https://dx.doi.org/10.1111/eci.13220. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Tipologia:
Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso:
Licenza specifica dell’editore
Dimensione
1.11 MB
Formato
Adobe PDF
|
1.11 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.